All Pharmaceutical Microbiology articles – Page 11
-
NewsAcoziborole Winthrop receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
The European Medicines Agency has granted a positive opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults as well as in adolescents 12 years and older weighing at least 40 kilograms.
-
NewsScientists identify key protein that stops malaria parasite growth
An international team of scientists have identified a unique protein essential for the malaria parasite’s survival and transmission. Aurora-related kinase 1 (ARK1) acts as a ‘traffic controller’ during the parasite’s unusual cell division and growth process.
-
NewsScientists uncover mechanism used by three bacteria-killing viruses to target transporter
Biochemists have homed in on an underexplored small transporter called MurJ that is a vital part of the pathway bacteria use to build their chain-mail-like cell wall. Using advanced tools, the scientists have determined the common mechanism used by three different bacteria-killing viruses to block MurJ from doing its job.
-
NewsScientists identify endangered natural pharmacy hidden in coral reefs
The magnitude of the potential loss of the “natural pharmacy” found in the coral microbiome is demonstrated by a new study which identified new microbial species in corals which have the ability to produce novel substances.
-
NewsEmerging class of antibiotics to tackle global tuberculosis crisis
Researchers investigated how three naturally occurring antibiotic compounds – ecumicin, ilamycin and cyclomarin – act on a vital protein degradation machine inside Mycobacterium tuberculosis, the bacterium that causes TB.
-
NewsSingle daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens
A phase 3 clinical trial has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and lenacapavir (BIC/LEN) – may simplify treatment significantly for people with HIV who currently take very complex treatments.
-
NewsStudying yeast in the gut could lead to new, better drugs
A new study sheds light on the behavior of yeast cells in the gut, paving the way for new lines of yeast that more efficiently produce therapeutic drugs tailored to address specific diseases.
-
NewsNew strategies aim at HIV’s last strongholds
A new study has overcome a long-standing challenge—how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease difficult to cure.
-
News Huayunuo approval positions China at forefront of viral hepatitis innovation, says GlobalData
Huahui Health has recently secured conditional approval from China for Huayunuo (Libevitug Injection), marking it as the first domestically developed monoclonal antibody (mAb) drug for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis.
-
NewsNew insights into how bacteria control DNA synthesis open the door to next generation antimicrobials
A new study combines structural biology, biophysical characterisation and functional assays to delineate how the bacterial transcriptional regulator NrdR’s quaternary structure responds to different nucleotide states and how these changes affect its regulatory activity.
-
NewsInvasive death cap mushrooms are changing their chemistry
Scientists have just published new research about the chemistry of death cap mushrooms (Amanita phalloides) - the species is not only spreading rapidly as an invasive fungal species in the United States, but the move across continents has changed the chemistry of the species.
-
NewsNew antibody–drug conjugate strategy to block HIV infection
New antibody–drug conjugates (ADCs) combine a CD4 mimic with neutralizing antibodies for enhanced suppression of HIV infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry.
-
NewsA yeast enzyme helps human cells overcome mitochondrial defects
An international team has experimentally uncoupled nucleotide synthesis from mitochondrial activity using ScURA, a yeast-derived genetic tool now available to the research community that will enable new explorations of cellular metabolism.
-
NewsRhododendron-derived drugs now made by bacteria
Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities. The compounds, orsellinic acid-derived meroterpenoids, are produced by Rhododendron species.
-
NewsImmunity against common virus leveraged against pancreatic cancer
Researchers have discovered a promising new treatment approach for pancreatic cancer. The approach leverages the body’s natural immune response to cytomegalovirus (CMV), a common but typically harmless virus that most people are infected with at some point in their lives.
-
NewsHIV antibody opens up new approaches for vaccine development and combination therapies
An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. The study opens up new perspectives for the development of vaccines and therapeutics against HIV-1.
-
NewsBasic research on Listeria bacteria leads to unique cancer therapy
After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, researchers have discovered a way to turn the bacteria into a potent booster of the immune system — and a potential weapon against cancer.
-
NewsResearchers develop new inhalable treatment for TB
Researchers have developed an inhalable, immunomodulating, biocompatible nanoparticle system encapsulating rifampin, one of the most important TB drugs.
-
NewsVirus-based therapy boosts anti-cancer immune responses to brain cancer
A study has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors.
-
NewsShorter treatment regimens are safe options for preventing active tuberculosis
A study comparing one- and three-month antibiotic treatments to prevent active tuberculosis (TB) finds that a high percentage of patients successfully completed both regimens and suffered few adverse side effects.